Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal and Bone Safety of TAF Switch in CHB Patients
NCT02957994Phase 4Unknown
- Sponsor
- Coalition of Inclusive Medicine
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Coalition of Inclusive Medicine. Primary endpoints: Markers of renal function at 1 year and Bone density at 1 year. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02957994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957994.